- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.
Sydney, 25 June 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss the company’s recent activities.
A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.
A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.
Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work.
Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked